226250-03-9

Basic information

• Product Name: 1H-BenziMidazole-1-carboxylicacid,6-(broMoMethyl)-,1,1-diMethylethylester
• Synonyms: 1H-BenziMidazole-1-carboxylicacid,6-(broMoMethyl)-,1,1-diMethylethylester;tert-Butyl 6-(bromomethyl)-1H-benzo[d]imidazole-1-carboxylate
• CAS NO: 226250-03-9
• Molecular Formula: C₁₃H₁₅BrN₂O₂
• Molecular Weight: 311.1744
• Mol File: 226250-03-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1H-BenziMidazole-1-carboxylicacid,6-(broMoMethyl)-,1,1-diMethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-BenziMidazole-1-carboxylicacid,6-(broMoMethyl)-,1,1-diMethylethylester(226250-03-9)
• EPA Substance Registry System: 1H-BenziMidazole-1-carboxylicacid,6-(broMoMethyl)-,1,1-diMethylethylester(226250-03-9)

Safety Data

• Hazardous Substances Data: 226250-03-9(Hazardous Substances Data)

Usage

Class

Benzimidazoles

Physical state

White solid

Molecular weight

345.217 g/mol

Use in medicinal chemistry and pharmaceutical research

Building block for the synthesis of biologically active compounds

Use as an intermediate

Production of pharmaceuticals, agrochemicals, and other fine chemicals

Potential applications

Development of antiviral, antifungal, and anticancer drugs.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 614-97-1 5-methylbenzimidazole 
• 863877-82-1 tert-butyl 6-methyl-1H-benzo[d]imidazole-1-carboxylate 
• 863877-81-0 tert-butyl 5-methyl-1H-benzo[d]imidazole-1-carboxylate 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.